鉴定了thalidomide重毒性的主要标
Takumi Ito1, Hideki Ando, Takayuki Suzuki
1Integrated Research Institute, Tokyo Institute of Technology, Yokohama 226-8503, Japan.
概括
塔利多米德通过与大脑蛋白 (CRBN) 结合而导致出生缺陷,这是一种E3泛素结合酶. 这项研究确定了CRBN作为thalidomide的目标,揭示了其致病作用背后的机制.
科学领域:
- 发育生物学 发展生物学
- 分子药理学分子药理学
- 甲状腺学 甲状腺学
背景情况:
- 塔利多米德是一种用于治疗麻风和多发性骨髓瘤的药物,此前已知会导致严重的出生缺陷.
- 塔利多米德诱导原性,特别是四肢形的确切机制仍然未知.
研究的目的:
- 为了确定塔利多米德的蛋白标,负责其原性作用.
- 阐明泰利多米德诱导的发育缺陷背后的分子机制.
主要方法:
- 蛋白质 - 配体结合测试以确定thalidomide结合蛋白.
- 生物化学分析E3无素结合酶复合体的形成和活性.
- 在斑马鱼和小模型中的体内研究,以评估四肢发育和基因表达.
主要成果:
- 鉴定出cereblon (CRBN) 是与thalidomide结合的特定蛋白质.
- CRBN与DDB1和Cul4A一起形成一个功能性的E3泛基因酶复合体,对肢体外生和Fgf8表达至关重要.
- 塔利多米德与CRBN结合,抑制了E3无素结合酶的活性,从而启动了原性作用.
结论:
- 这项研究确立了CRBN作为调解thalidomide产性的分子标.
- 了解这种机制为开发具有降低或没有原性潜力的更安全的thalidomide类似物提供了基础.
相关概念视频
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

